Thomas Smith
Stock Analyst at Leerink Partners
(2.75)
# 1,789
Out of 5,152 analysts
60
Total ratings
35.09%
Success rate
10.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGMB AgomAb Therapeutics NV | Initiates: Outperform | $36 | $14.50 | +148.28% | 1 | Mar 3, 2026 | |
| IVA Inventiva | Initiates: Outperform | $12 | $6.12 | +96.08% | 1 | Jan 12, 2026 | |
| ALMS Alumis | Maintains: Outperform | $20 → $32 | $27.81 | +15.07% | 2 | Jan 7, 2026 | |
| EVMN Evommune | Initiates: Outperform | $42 | $24.36 | +72.45% | 1 | Dec 1, 2025 | |
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $1.70 | -41.00% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $4.57 | +96.94% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $2.99 | +134.51% | 7 | Nov 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $7.23 | +439.42% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $5.50 | +373.16% | 1 | Mar 25, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $113.69 | -82.41% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $430 → $435 | $722.87 | -39.82% | 3 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $60.37 | -40.37% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $2.53 | +176.68% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $26.64 | -21.17% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $29.63 | +51.87% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $12.88 | -53.42% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $2.93 | +104.78% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $1.21 | +314.94% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $18.05 | -5.82% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $29.49 | +117.02% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $17.10 | +309.36% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $2.62 | +894.26% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $30.98 | -61.27% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $675 → $400 | $30.65 | +1,205.06% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $12.24 | +553.59% | 2 | Dec 8, 2020 |
AgomAb Therapeutics NV
Mar 3, 2026
Initiates: Outperform
Price Target: $36
Current: $14.50
Upside: +148.28%
Inventiva
Jan 12, 2026
Initiates: Outperform
Price Target: $12
Current: $6.12
Upside: +96.08%
Alumis
Jan 7, 2026
Maintains: Outperform
Price Target: $20 → $32
Current: $27.81
Upside: +15.07%
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $42
Current: $24.36
Upside: +72.45%
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $1.70
Upside: -41.00%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $4.57
Upside: +96.94%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $2.99
Upside: +134.51%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $7.23
Upside: +439.42%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $5.50
Upside: +373.16%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $113.69
Upside: -82.41%
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $722.87
Upside: -39.82%
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $60.37
Upside: -40.37%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $2.53
Upside: +176.68%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $26.64
Upside: -21.17%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $29.63
Upside: +51.87%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $12.88
Upside: -53.42%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $2.93
Upside: +104.78%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $1.21
Upside: +314.94%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $18.05
Upside: -5.82%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $29.49
Upside: +117.02%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $17.10
Upside: +309.36%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $2.62
Upside: +894.26%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $30.98
Upside: -61.27%
Mar 16, 2021
Maintains: Outperform
Price Target: $675 → $400
Current: $30.65
Upside: +1,205.06%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $12.24
Upside: +553.59%